Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
advice, begun, blockade, booster, capacity, checkpoint, clarity, composition, counsel, credit, denial, Department, exhibit, Fifty, flare, Food, fulfill, goal, high, immunotherapeutic, individually, induction, Jersey, judicial, Justice, largely, legal, letter, lifted, lifting, maintenance, Mechanistically, monoclonal, mutually, nivolumab, notified, official, Opdivo, ordinary, pharmacokinetic, potency, Prepaid, Pretrial, protocol, recover, recovery, regulating, remove, stability, strive, Summit, thirty, timepoint, twenty, typically, unable, unvested, verbal, vest, withdrew
Removed:
adding, additive, adequately, AEs, alleging, alternative, animal, annually, annum, ASPIN, assumption, asymptomatic, attributable, bifurcation, block, British, cccDNA, cell, chain, clinically, cohort, collected, Columbia, commence, commenced, community, compensate, compliance, compounded, compounding, computing, conduct, consisting, consolidation, converted, coupon, currency, cycle, deficit, delayed, demonstrate, digit, disoproxil, disrupt, disrupted, disruption, double, driven, economy, emergent, enabling, enrolled, ensuing, evacuation, expired, feature, fixed, foreign, formation, fumarate, GAAP, generate, governmental, growth, hospital, impaired, implemented, inability, incur, initially, instituted, intact, interrupted, invalidity, invasion, investigate, jeopardize, leaving, led, lockup, lost, magnitude, mandate, mandatory, meaningful, military, mission, monitoring, movement, National, netted, noted, Nucleotide, PA, pandemic, pangenotypic, participate, persist, persistence, petition, planned, plateau, predetermined, prioritization, ratio, reallocation, redemption, relevant, reservoir, restrict, ruling, Russia, selectively, serum, settled, significantly, site, spread, standstill, state, statistically, step, subscription, suspended, tenofovir, tolerated, triple, UBC, Ukraine, uncoating, undeniable, undertaken, University, upholding, valid, violence, Viread, vital, volatility, war, warfare, Warminster, wholly, work, world
Filing tables
Filing exhibits
Related press release
Associated ABUS transcripts
ABUS similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I William Collier, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.
Date: May 4, 2023
| /s/ William Collier | |||||
| Name: William Collier | |||||
| Title: President and Chief Executive Officer | |||||